Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

SIMPLE SUMMARY: This study is to examine the clinical and pathologic characteristics and survival in patients who received neoadjuvant FOLFINOX or neoadjuvant gemcitabine/nab-paclitaxel (GemNP) followed by surgery with curative intent. Our study demonstrated that neoadjuvant FOLFIRINOX treatment is...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Yi Tat, Lai, Zongshan, Katz, Matthew H. G., Prakash, Laura R, Wang, Hua, Chatterjee, Deyali, Kim, Michael, Tzeng, Ching-Wei D., Lee, Jeffrey E., Ikoma, Naruhiko, Rashid, Asif, Wolff, Robert A., Zhao, Dan, Koay, Eugene J., Maitra, Anirban, Wang, Huamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177033/
https://www.ncbi.nlm.nih.gov/pubmed/37174073
http://dx.doi.org/10.3390/cancers15092608

Ejemplares similares

Ejemplares similares